Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: Insights from the VERDI study

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 385-398

  Halimi, Serge ^a   Levy, Marc ^b   Huet, Dominique ^c   Quéré, Stéphane ^d   Dejager, Sylvie ^d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Max Fourestier Hospital   (France)

^c SAINT JOSEPH HOSPITAL   (France)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Hypoglycemia; Insulin secretagogues; Metformin; Ramadan; Type 2 diabetes; Vildagliptin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN SECRETAGOGUE; METFORMIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; DIET RESTRICTION; DISEASE DURATION; DIZZINESS; FEMALE; FOLLOW UP; FRANCE; GLYCEMIC CONTROL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; WEIGHT CONTROL;

EID: 84892457831     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0038-7     Document Type: Article

References (37)

1. International Diabetes Federation. Diabetes Atlas Update 2012, 5th ed. Brussels, Belgium: International Diabetes Federation; 2012. e-linkurlhttp:///url/e-linkwww.idf.org/diabetesatlas/5e/Update2012. Last accessed 1 June 2013.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.
3. Bashir MI, Pathan MF, Raza SA, et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab. 2012;16:503-7.
4. Al Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33:1895-902.
5. Pew Research Center's Forum on Religion & Public Life. http://www.pewforum.org/2011/01/27/the-future-of-the-global-muslim-population/#europe. Last accessed 20 Aug 2013.
6. Rashed AH. The fast of Ramadan. BMJ. 1992;304:521-2.
7. Burden M. Culturally sensitive care: managing diabetes during Ramadan. Br J Community Nurs. 2001;6:581-5.
8. Davidson MB. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2006;29:745.
9. Elhadd TA, Al Amoudi AA. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2006;29:744-5.
10. Almaatouq MA. Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes Metab Syndr Obes. 2012;5:109-19.
11. Salti I, Benard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306-11.
12. Ahmad J, Pathan MF, Jaleel MA, et al. Diabetic emergencies including hypoglycemia during Ramadan. Indian J Endocrinol Metab. 2012;16: 512-5.
13. Hui E, Devendra D. Diabetes and fasting during Ramadan. Diabetes Metab Res Rev. 2010;26:606-10.
14. Zargar A, Basit A, Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc. 2005;103: 444-6.
15. Zargar AH, Siraj M, Jawa AA, Hasan M, Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract. 2010;64:1090-4.
16. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58:45-53.
17. The Glimepiride in Ramadan (GLIRA) Study group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care. 2005;28: 421-2.
18. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27: 1367-74.
19. Aravind SR, Tayeb KA, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27:1237-42.
20. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011;2:51-66.
21. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population C75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13:55-64.
22. Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract (1995). 2012;40:7-21.
23. Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract. 2013;41:93-107.
24. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11: 157-66.
25. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780-9.
26. Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63:1446-50.
27. Gaborit B, Dutour O, Ronsin O, et al. Ramadan fasting with diabetes: an interview study of inpatients' and general practitioners' attitudes in the South of France. Diabetes Metab. 2011;37: 395-402.
28. Mygind A, Kristiansen M, Wittrup I, Norgaard LS. Patient perspectives on type 2 diabetes and medicine use during Ramadan among Pakistanis in Denmark. Int J Clin Pharm. 2013;35:281-8.
29. Bravis V, Hui E, Salih S, Mehart S, Hassanein M, Devendra D. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan. Diabet Med. 2010;27:327-31.
30. Ahmedani MY, Haque MS, Basit A, Fawwad A, Alvi SF. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med. 2012;29:709-15.
31. Halimi S, Levy M, Amghar H. Clinical case: beliefs, Ramadan and diabetes mellitus. Ann Endocrinol (Paris). 2004;65(1 Suppl):S68-73 (In French).
32. Hassanein M, Bravis V, Hui E, Devendra D. Ramadan-focused education and awareness in type 2 diabetes. Diabetologia. 2009;52:367-8.
33. Al-Arouj M, Hassoun A, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Diabetes. 2013;62:A288-9 (Abstract 1112-P).
34. Hanif W, Malik W, Hassanein M, et al. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Curr Med Res Opin. 2013;29:807-11.
35. Penfornis A, Bourdel-Marchasson I, Quere S, Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab. 2012;38:550-7.
36. Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132-40.
37. Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28: 1289-96.